anti-herpetic

Acyclovir (Aciclovir) is a guanine analog and orally active antiviral agent characterized by a narrow antiviral spectrum, high selectivity, and low toxicity. Acyclovir exhibits activity against HSV-1 (IC50 = 0.85 μM), HSV-2 (IC50 = 0.86 μM), and varicella-zoster virus. Acyclovir can be used for herpesvirus treatment research.

Desciclovir (DCV), a prodrug of the antiherpetic agent acyclovir (ACV), is converted in humans to ACV, presumably by xanthine oxidase.

Eprociclovir (A-5021) is a novel acyclovir analog that is a potent inhibitor of EHV1 replication and may be used for the treatment and/or prevention of infections with this virus.Eprociclovir has potent anti-herpetic activity against most human herpesviruses.

Acyclovir (Aciclovir) hydrochloride is an effective oral antiviral agent with potent anti-herpetic activity. It exhibits IC50 values of 0.85 μM for HSV-1 and 0.86 μM for HSV-2, indicating strong inhibitory effects against these strains. Additionally, Acyclovir hydrochloride induces cell cycle disturbances and apoptosis. This compound also prevents bacterial infections during induction therapy for acute leukemia.

Eprociclovir dihydrate is a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.

Eprociclovir Na is the salt form of Eprociclovir, also known as A-5021, a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.

Eprociclovir potassium is a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.

Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.

Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a mouse-derived inhibitory antibody that targets mouse 4-1BBL/CD137L and blocks 4-1BB ligand (4-1BBL), thereby inhibiting the activity of CD4+ and CD8+ T cells, and is suitable for research related to cancer, infection, inflammation and immunology, specifically applicable to models such as MC38 tumor, lymphocytic choriomeningitis virus (LCMV) infection, and herpetic stromal keratitis (HSK).